BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 38457494)

  • 21. Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia with e1a3 BCR-ABL1 transcript in a Nigerian with sickle cell anemia: a case report.
    Ahmed IO; Ochogwu LO; Owojuyigbe TO; Akinola NO; Durosinmi MA
    J Med Case Rep; 2021 Oct; 15(1):504. PubMed ID: 34625105
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IGJ and SPATS2L immunohistochemistry sensitively and specifically identify BCR::ABL1+ and BCR::ABL1-like B-acute lymphoblastic leukaemia.
    Gestrich CK; De Lancy SJ; Kresak A; Meyerson H; Pateva I; Yalley AK; Ryder C; Shetty S; Bledsoe J; Moore EM; Oduro KA
    Br J Haematol; 2024 Jan; 204(1):229-239. PubMed ID: 37871900
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The BCR-ABL1 kinase bypasses selection for the expression of a pre-B cell receptor in pre-B acute lymphoblastic leukemia cells.
    Klein F; Feldhahn N; Harder L; Wang H; Wartenberg M; Hofmann WK; Wernet P; Siebert R; Müschen M
    J Exp Med; 2004 Mar; 199(5):673-85. PubMed ID: 14993251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.
    van der Veer A; Waanders E; Pieters R; Willemse ME; Van Reijmersdal SV; Russell LJ; Harrison CJ; Evans WE; van der Velden VH; Hoogerbrugge PM; Van Leeuwen F; Escherich G; Horstmann MA; Mohammadi Khankahdani L; Rizopoulos D; De Groot-Kruseman HA; Sonneveld E; Kuiper RP; Den Boer ML
    Blood; 2013 Oct; 122(15):2622-9. PubMed ID: 23974192
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transcriptomic classes of BCR-ABL1 lymphoblastic leukemia.
    Kim JC; Chan-Seng-Yue M; Ge S; Zeng AGX; Ng K; Gan OI; Garcia-Prat L; Flores-Figueroa E; Woo T; Zhang AXW; Arruda A; Chithambaram S; Dobson SM; Khoo A; Khan S; Ibrahimova N; George A; Tierens A; Hitzler J; Kislinger T; Dick JE; McPherson JD; Minden MD; Notta F
    Nat Genet; 2023 Jul; 55(7):1186-1197. PubMed ID: 37337105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
    Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A
    Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adult acute lymphoblastic leukemia with a rare b3a3 type BCR/ABL1 fusion transcript.
    Kurita D; Hatta Y; Hojo A; Kura Y; Sawada U; Kanda Y; Takei M
    Cancer Genet; 2016 Apr; 209(4):161-5. PubMed ID: 26854094
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working Party.
    Iacobucci I; Lonetti A; Paoloni F; Papayannidis C; Ferrari A; Storlazzi CT; Vignetti M; Cilloni D; Messa F; Guadagnuolo V; Paolini S; Elia L; Messina M; Vitale A; Meloni G; Soverini S; Pane F; Baccarani M; Foà R; Martinelli G
    Haematologica; 2010 Oct; 95(10):1683-90. PubMed ID: 20534699
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia.
    Srutova K; Curik N; Burda P; Savvulidi F; Silvestri G; Trotta R; Klamova H; Pecherkova P; Sovova Z; Koblihova J; Stopka T; Perrotti D; Polakova KM
    Haematologica; 2018 Dec; 103(12):2016-2025. PubMed ID: 30049824
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ABL1 gene deletion without BCR/ABL1 rearrangement in a young adolescent with precursor B-cell acute lymphoblastic leukemia: clinical study and literature review.
    Kim MJ; Yoon HS; Lim G; Kim SY; Lee HJ; Suh JT; Lee J; Lee WI; Park TS
    Cancer Genet Cytogenet; 2010 Jan; 196(2):184-8. PubMed ID: 20082857
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Laboratory testing in BCR-ABL1-like (Philadelphia-like) B-lymphoblastic leukemia/lymphoma.
    Siegele BJ; Nardi V
    Am J Hematol; 2018 Jul; 93(7):971-977. PubMed ID: 29696694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The e1a3
    Chen Z
    Hematology; 2023 Dec; 28(1):2186040. PubMed ID: 36912524
    [No Abstract]   [Full Text] [Related]  

  • 33. BCR-ABL1-like B-lymphoblastic leukemia/lymphoma: Review of the entity and detection methodologies.
    Conant JL; Czuchlewski DR
    Int J Lab Hematol; 2019 May; 41 Suppl 1():126-130. PubMed ID: 31069976
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1.
    Gu S; Chan WW; Mohi G; Rosenbaum J; Sayad A; Lu Z; Virtanen C; Li S; Neel BG; Van Etten RA
    Blood; 2016 Apr; 127(14):1803-13. PubMed ID: 26773044
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergism between IL7R and CXCR4 drives BCR-ABL induced transformation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Abdelrasoul H; Vadakumchery A; Werner M; Lenk L; Khadour A; Young M; El Ayoubi O; Vogiatzi F; Krämer M; Schmid V; Chen Z; Yousafzai Y; Cario G; Schrappe M; Müschen M; Halsey C; Mulaw MA; Schewe DM; Hobeika E; Alsadeq A; Jumaa H
    Nat Commun; 2020 Jun; 11(1):3194. PubMed ID: 32581241
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SFPQ-ABL1 and BCR-ABL1 use different signaling networks to drive B-cell acute lymphoblastic leukemia.
    Brown LM; Hediyeh-Zadeh S; Sadras T; Huckstep H; Sandow JJ; Bartolo RC; Kosasih HJ; Davidson NM; Schmidt B; Bjelosevic S; Johnstone R; Webb AI; Khaw SL; Oshlack A; Davis MJ; Ekert PG
    Blood Adv; 2022 Apr; 6(7):2373-2387. PubMed ID: 35061886
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression.
    Bueno MJ; Pérez de Castro I; Gómez de Cedrón M; Santos J; Calin GA; Cigudosa JC; Croce CM; Fernández-Piqueras J; Malumbres M
    Cancer Cell; 2008 Jun; 13(6):496-506. PubMed ID: 18538733
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting of heme oxygenase-1 attenuates the negative impact of Ikaros isoform 6 in adult BCR-ABL1-positive B-ALL.
    Lin X; Zou X; Wang Z; Fang Q; Chen S; Huang J; Zhe N; Yu M; Zhang Y; Wang J
    Oncotarget; 2016 Aug; 7(33):53679-53701. PubMed ID: 27447561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute lymphoblastic leukaemia with an e1a3 BCR-ABL1 fusion.
    Langabeer SE; Haslam K; Kelly J; Leahy M; Vandenberghe E
    Acta Haematol; 2011; 126(4):214-5. PubMed ID: 21934295
    [No Abstract]   [Full Text] [Related]  

  • 40. A novel targeted RNA-Seq panel identifies a subset of adult patients with acute lymphoblastic leukemia with BCR-ABL1-like characteristics.
    Sánchez R; Ribera J; Morgades M; Ayala R; Onecha E; Ruiz-Heredia Y; Juárez-Rufián A; de Nicolás R; Sánchez-Pina J; Vives S; Zamora L; Mercadal S; Coll R; Cervera M; García O; Ribera JM; Martínez-López J
    Blood Cancer J; 2020 Apr; 10(4):43. PubMed ID: 32332702
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.